Valuation: Virbac

Market Cap 2.8B 3.19B 2.6B 2.39B 4.49B 308B 4.58B 31.09B 12.13B 151B 11.96B 11.71B 522B P/E 2026 *
16.4x
P/E 2027 * 14.8x
Enterprise Value 2.93B 3.33B 2.72B 2.5B 4.69B 322B 4.78B 32.49B 12.68B 158B 12.5B 12.24B 546B EV / Sales 2026 *
1.89x
EV / Sales 2027 * 1.75x
Free-Float
49.03%
Yield 2026 *
0.52%
Yield 2027 * 0.61%
1 day-6.07%
1 week-6.07%
Current month-6.07%
1 month-6.07%
3 months-0.39%
6 months-12.16%
Current year-12.16%
1 week 382.75
Extreme 382.75
413.75
1 month 382.75
Extreme 382.75
413.75
Current year 382.75
Extreme 382.75
413.75
1 year 382.75
Extreme 382.75
436.32
3 years 288
Extreme 288
436.32
5 years 288
Extreme 288
436.32
10 years 131
Extreme 131
436.32
Manager TitleAgeSince
Chief Executive Officer 46 2025-08-31
Chief Executive Officer 50 2024-09-26
Chief Operating Officer 64 2021-12-31
Director TitleAgeSince
Chairman 61 2006-03-31
Director/Board Member 68 2010-07-27
Director/Board Member 65 2017-09-04
Change 5-day change 1-year change 3-year change Capi.($)
-6.07%-6.07% - - 3.35B
+0.51%+0.05%-50.68%-59.36% 31.1B
-2.21%-2.98%+65.97%+106.16% 12.66B
+1.84%+5.45%-19.46%+1.84% 3.72B
+2.30%-5.32%+32.72%+12.78% 1.82B
-1.62%+6.19%-4.76%+22.62% 1.86B
+0.68%+0.89%+16.46%+127.84% 1.37B
+1.01%-1.29%-24.79%-13.46% 1.07B
+0.78%-0.77%-17.26%-47.86% 968M
-1.26%-2.48%-8.76%-21.25% 951M
Average -0.40%+1.07%-1.17%+14.37% 6.17B
Weighted average by Cap. -0.39%+0.14%-14.26%-6.06%

Financials

2026 *2027 *
Net sales 1.55B 1.76B 1.44B 1.32B 2.48B 170B 2.53B 17.19B 6.71B 83.42B 6.62B 6.48B 289B 1.65B 1.87B 1.53B 1.41B 2.64B 181B 2.69B 18.26B 7.13B 88.62B 7.03B 6.88B 307B
Net income 171M 195M 159M 146M 274M 18.81B 279M 1.9B 741M 9.21B 731M 715M 31.9B 190M 216M 177M 162M 304M 20.87B 310M 2.11B 822M 10.22B 811M 794M 35.41B
Net Debt 127M 144M 118M 108M 203M 13.93B 207M 1.41B 549M 6.82B 541M 530M 23.63B 75.16M 85.52M 69.84M 64.22M 120M 8.26B 123M 834M 325M 4.05B 321M 314M 14.01B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
334.50EUR
Average target price
412.00EUR
Spread / Average Target
+23.17%

Quarterly revenue - Rate of surprise